Loading...
Loading...
Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp.. Spoken Alpha tracks TTIPF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks TTIPF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TTIPF.
curl https://api.spokenalpha.com/v1/companies/TTIPF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.56 | $1.85 | +38.2% | -7.7% | -5.8% |
| Q4 FY2026 | $2.21 | $1.66 | +33.3% | -3.8% | -3.6% |
| Q3 FY2026 | $2.55 | $1.85 | +38.1% | -3.1% | -0.3% |
| Q2 FY2026 | $2.27 | $1.75 | +29.5% | -6.5% | -8.2% |
| Q1 FY2025 | $2.65 | $1.88 | +41.0% | +2.4% | +2.4% |
| Q4 FY2025 | $2.50 | $1.82 | +37.4% | -1.1% | +0.2% |
| Q3 FY2025 | $2.63 | $1.99 | +32.4% | -6.6% | -4.2% |
| Q2 FY2025 | $2.51 | $1.91 | +31.2% | -3.1% | -3.7% |
| Q1 FY2024 | $2.57 | $2.02 | +27.3% | -1.4% | +0.2% |
| Q4 FY2024 | $2.79 | $1.97 | +41.8% | +3.3% | +3.3% |